Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of Medicinal Chemistry

• Publication date

  1998-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/JM9804174PMID 9857095
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ligand binding affinity prediction by linear interaction energy methods

  1998cited by this paper
• Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities.

  1997cited by this paper
• Binding affinities for sulfonamide inhibitors with human thrombin using Monte Carlo simulations with a linear response method.

  1997cited by this paper
• Molecular modeling of HIV-1 reverse transcriptase drug-resistant mutant strains: implications for the mechanism of polymerase action.

  1997cited by this paper
• HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors.

  1996cited by this paper
• Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.

  1996cited by this paper
• Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors

  1995cited by this paper
• Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors

  1995cited by this paper
• The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1.

  1995cited by this paper
• Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo-[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TlBO) derivatives. 4.

  1995cited by this paper
• Molecular modeling studies of HIV‐1 reverse transcriptase nonnucleoside inhibitors: Total energy of complexation as a predictor of drug placement and activity

  1995cited by this paper
• Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution.

  1995cited by this paper
• Estimation of binding free energies for HIV proteinase inhibitors by molecular dynamics simulations.

  1995cited by this paper
• Insights into DNA polymerization mechanisms from structure and function analysis of HIV-1 reverse transcriptase.

  1995cited by this paper
• Comparison of three different crystal forms shows HIV-1 reverse transcriptase displays an internal swivel motion.

  1994cited by this paper
• A new method for predicting binding affinity in computer-aided drug design.

  1994cited by this paper
• Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1.

  1994cited by this paper
• Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA.

  1993cited by this paper
• Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.

  1992cited by this paper
• Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication.

  1991cited by this paper
• Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a non-nucleoside dipyridodiazepinone, BI-RG-587, using a heteropolymeric template.

  1991cited by this paper
• The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin.

  1988cited by this paper
• Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

  1973cited by this paper

• AILDE Computer-Aided Discovery of Novel Ibuprofen–Coumarin Antitumor Lead Compounds Targeting Cyclooxygenase-2

  2024cites this paper
• Computationally predicting binding affinity in protein-ligand complexes: free energy-based simulations and machine learning-based scoring functions

  2020cites this paper
• Auto In Silico Ligand Directing Evolution to Facilitate the Rapid and Efficient Discovery of Drug Lead

  2020cites this paper
• Synthesis, crystal structure and Hirshfeld surface analysis of 3-(4,4-dimethyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-2-ylidene)-6-methyl-3,4-dihydro-2H-pyran-2,4-dione

  2019cites this paper
• The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.

  2018cites this paper
• AIMMS suite: a web server dedicated for prediction of drug resistance on protein mutation

  2018cites this paper
• A QSAR Model for Predicting the Anti HIV‐1 Activity of TIBO Derivatives Using the Norm Indexes

  2016cites this paper
• Computer-aided discovery of anti-HIV agents.

  2016cites this paper
• Molecular modeling of sulfoxaflor and neonicotinoid binding in insect nicotinic acetylcholine receptors: impact of the Myzus β1 R81T mutation.

  2016cites this paper
• Theoretical studies of energetics and binding isotope effects of binding a triazole-based inhibitor to HIV-1 reverse transcriptase.

  2016cites this paper
• Structural and functional consequences of single mutations at the high affinity binding site of cyanovirin-N

  2016cites this paper
• Docking and Ligand Binding Affinity: Uses and Pitfalls

  2016cites this paper
• Linking electrostatic effects and protein motions in enzymatic catalysis. A theoretical analysis of catechol o-methyltransferase.

  2015cites this paper
• Binding isotope effects as a tool for distinguishing hydrophobic and hydrophilic binding sites of HIV-1 RT.

  2015cites this paper
• A Simple and Advantageous Synthesis of the Privileged 1,4-Benzodiazepine Nucleus

  2014cites this paper
• 1,5‐Benzodiazepines. Overview of Properties and Synthetic Aspects

  2014cites this paper
• QSAR and docking studies on the diaryltriazine analogs as HIV-1 reverse transcriptase inhibitors

  2014cites this paper
• Molecular dynamics and free energy studies of chirality specificity effects on aminobenzo[a]quinolizine inhibitors binding to DPP-IV

  2013cites this paper
• Flooding Enzymes: Quantifying the Contributions of Interstitial Water and Cavity Shape to Ligand Binding Using Extended Linear Response Free Energy Calculations

  2013cites this paper
• Predictions of Enzymatic Parameters: A Mini-Review with Focus on Enzymes for Biofuel

  2013cites this paper
• Effects of the protonation state of the catalytic residues and ligands upon binding and recognition in targeted proteins of HIV-1 and influenza viruses.

  2013cites this paper
• Toward improved drug discovery against flexible protein targets: An exhaustive study of glutamate racemase conformational dynamics, ligand binding, and catalysis

  2013cites this paper
• Molecular Dynamics Investigation on a Series of HIV Protease Inhibitors: Assessing the Performance of MM-PBSA and MM-GBSA Approaches

  2012cites this paper
• Advances and applications of binding affinity prediction methods in drug discovery.

  2012cites this paper
• Computational Studies of Darunavir into HIV-1 Protease and DMPC Bilayer: Necessary Conditions for Effective Binding and the Role of the Flaps

  2012cites this paper
• (5,7-Dimethyl-2-oxo-2H-chromen-4-yl)methyl diethyldithiocarbamate

  2012cites this paper
• Estimation of the binding free energy by Linear Interaction Energy models.

  2012cites this paper
• The role of hydrogen bonds in protein–ligand interactions. DFT calculations in 1,3‐dihydrobenzimidazole‐2 thione derivatives with glycinamide as model HIV RT inhibitors

  2012cites this paper
• 2D QSAR Study of Some TIBO Derivatives as an Anti HIV Agent

  2012cites this paper
• Synthesis and Anticonvulsant Activity of Various Mannich and Schiff Bases of 1,5-Benzodiazepines

  2012cites this paper
• Multi-Site λ-dynamics for simulated Structure-Activity Relationship studies.

  2011cites this paper
• Challenges for Computer Simulations in Drug Design

  2010cites this paper
• Drug Design: Computer-aided drug design: a practical guide to protein-structure-based modeling

  2010cites this paper
• 1,5-Dimethyl-3-[(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)methyl]-1H-1,5-benzodiazepine-2,4(3H,5H)-dione

  2010cites this paper
• Binding free energy calculations of N-sulphonyl-glutamic acid inhibitors of MurD ligase

  2009cites this paper
• Binding Free Energy Calculations of Adenosine Deaminase Inhibitor and the Effect of Methyl Substitution in Inhibitors

  2009cites this paper
• Validating CHARMM parameters and exploring charge distribution rules in structure-based drug design.

  2009cites this paper
• Analysis of structure and function of the giant protein Pf332 in Plasmodium falciparum

  2008influential citation
• Analysis of Structure and Function of the Giant Protein Pf 332 in Plasmodium falciparum

  2008influential citation
• A statistical rescoring scheme for protein–ligand docking: Consideration of entropic effect

  2008cites this paper
• Calculation of binding affinities of HIV-1 RT and β-secretase inhibitors using the linear interaction energy method with explicit and continuum solvation approaches

  2007cites this paper
• Electron-Topological Method of the non-nucleoside HIV-1 RT inhibitors study: structure-activity relationships.

  2007cites this paper
• Linear Interaction Energy (LIE) Models for Ligand Binding in Implicit Solvent:  Theory and Application to the Binding of NNRTIs to HIV-1 Reverse Transcriptase.

  2007cites this paper
• Molecular Dynamics Study on the Unbinding of HBY 097 in the K103N Mutant RT

  2007cites this paper
• Docking studies on the effect of β-ring expansion in binding of TIBO derivatives to HIV-1 reverse transcriptase

  2007cites this paper
• Computational inhibitor design against malaria plasmepsins

  2007cites this paper
• In Silico Binding Free Energy Predictability by Using the Linear Interaction Energy (LIE) Method: Bromobenzimidazole CK2 Inhibitors as a Case Study

  2007cites this paper
• Computer‐Aided Molecular Diversity Analysis and Combinatorial Library Design

  2007cites this paper
• A Rapid and Convenient Synthetic Route to Novel 1,5‐Benzodiazepine Derivatives of 5‐Methyl‐3‐phenyl‐2‐oxo‐Δ4‐1,3,4‐oxadiazolines from p‐Acetylphenylsydnone and Their Pharmacological Activity

  2006cites this paper
• Molecular mechanics methods for predicting protein-ligand binding.

  2006cites this paper
• Combining docking and molecular dynamic simulations in drug design

  2006cites this paper
• Linear interaction energy models for beta-secretase (BACE) inhibitors: Role of van der Waals, electrostatic, and continuum-solvation terms.

  2006cites this paper
• Computational study of the interaction between TIBO inhibitors and Y181 (C181), K101, and Y188 amino acids.

  2006cites this paper
• Calculation of the Relative Binding Affinity of Enzyme Inhibitors Using the Generalized Linear Response Method.

  2006cites this paper
• Design, Synthesis, Biological Evaluation, and Molecular Modeling Studies of TIBO‐Like Cyclic Sulfones as Non‐Nucleoside HIV‐1 Reverse Transcriptase Inhibitors

  2006cites this paper
• Towards predictive ligand design with free-energy based computational methods?

  2006cites this paper
• Minimalist explicit solvation models for surface loops in proteins.

  2006cites this paper
• The role of aspartic acid 143 in E. coli tRNA-guanine transglycosylase: insights from mutagenesis studies and computational modeling.

  2005cites this paper
• Modeling protein recognition of carbohydrates

  2005cites this paper
• Structure based activity prediction of HIV-1 reverse transcriptase inhibitors.

  2005cites this paper
• Peptide recognition by the T cell receptor: comparison of binding free energies from thermodynamic integration, Poisson–Boltzmann and linear interaction energy approximations

  2005cites this paper
• Applying linear interaction energy method for rational design of noncompetitive allosteric inhibitors of the sarco- and endoplasmic reticulum calcium-ATPase.

  2005cites this paper
• Computer-aided design of potential anti-HIV-1 non-nucleoside reverse transcriptase inhibitors by contraction of β-ring in TIBO derivatives

  2005cites this paper
• Where are we in HIV research? A novel, computer-based strategy predicting resistance to HIV-1 NNRTIs

  2005cites this paper
• Synthesis of spiro[indolo-1,5-benzodiazepines] from 3-acetyl coumarins for use as possible antianxiety agents

  2004cites this paper
• Relative free energy of binding and binding mode calculations of HIV‐1 RT inhibitors based on dock‐MM‐PB/GS

  2004cites this paper
• CoMFA 3D-QSAR Analysis of HIV-1 RT Nonnucleoside Inhibitors, TIBO Derivatives Based on Docking Conformation and Alignment

  2004cites this paper
• General model for estimation of the inhibition of protein kinases using Monte Carlo simulations.

  2004cites this paper
• Molecular recognition and docking algorithms.

  2003cites this paper
• Specific empirical free energy function for automated docking of carbohydrates to proteins

  2003cites this paper
• Molecular modeling calculations of HIV-1 reverse transcriptase nonnucleoside inhibitors: correlation of binding energy with biological activity for novel 2-aryl-substituted benzimidazole analogues.

  2003cites this paper
• Protein simulation and drug design.

  2003cites this paper
• Computer simulation studies of the fidelity of DNA polymerases

  2003cites this paper
• Protein-carbohydrate and protein-protein interactions: using models to better understand and predict specific molecular recognition

  2003cites this paper
• Analyses of activity for factor Xa inhibitors based on Monte Carlo simulations.

  2003cites this paper
• Protein flexibility and computer-aided drug design.

  2003cites this paper
• HIV-1 reverse transcriptase variants: molecular modeling of Y181C, V106A, L100I, and K103N mutations with nonnucleoside inhibitors using Monte Carlo simulations in combination with a linear response method.

  2003cites this paper
• Calculation of the binding affinity of beta-secretase inhibitors using the linear interaction energy method.

  2003cites this paper
• Docking of non‐nucleoside inhibitors: Neotripterifordin and its derivatives to HIV‐1 reverse transcriptase

  2002cites this paper
• Contributions to the binding free energy of ligands to avidin and streptavidin

  2002cites this paper
• 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 A resolution: kinetic and molecular dynamic correlates.

  2002cites this paper
• Structure-based QSAR study on differential inhibition of human prostaglandin endoperoxide H synthase-2 (COX-2) by nonsteroidal anti-inflammatory drugs

  2002cites this paper
• Hierarchy of simulation models in predicting structure and energetics of the Src SH2 domain binding to tyrosyl phosphopeptides.

  2002cites this paper
• Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations.

  2002cites this paper
• Molecular dynamics and free energy analyses of cathepsin D-inhibitor interactions: insight into structure-based ligand design.

  2002cites this paper
• Computational Advances in Structure Based Drug Design with Applications to HIV-1 Reverse Transcriptase

  2001cites this paper
• Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations.

  2001cites this paper
• Computer Aided Drug Design

  2001cites this paper
• Quantitative calculations of antibody--antigen binding: steroid--DB3 binding energies by the linear interaction energy method.

  2001cites this paper
• Can an optimization/scoring procedure in ligand-protein docking be employed to probe drug-resistant mutations in proteins?

  2001cites this paper
• Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA.

  2001cites this paper
• Monte Carlo calculations on HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor 8-Cl TIBO: contribution of the L100I and Y181C variants to protein stability and biological activity.

  2000cites this paper
• Major subdomain rearrangement in HIV‐1 reverse transcriptase simulated by molecular dynamics

  1999cites this paper